Sonoma Biotherapeutics Reports Promising Data from Phase 1 Trial
Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating SBT-77-7101 in patients with refractory rheumatoid arthritis (RA).
The data were presented at the 2025 American College of Rheumatology (ACR) Convergence in Chicago.
“We are very encouraged by these positive interim results from a first-in-human study of our proprietary program SBT-77-7101 in patients with refractory rheumatoid arthritis (RA), a severe form of RA that persists despite treatment with multiple conventional, biologic, and targeted synthetic therapies.” - Jeff Bluestone, Chief Executive Officer and President
SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA.
Author's summary: Sonoma Biotherapeutics reports positive results from a phase 1 trial for rheumatoid arthritis treatment.